Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by
blocking the enzymes necessary for cancer cell growth.
PURPOSE: This phase II trial is studying giving imatinib mesylate together with cytarabine to
see how well it works in treating patients with chronic phase chronic myelogenous leukemia.